<p>Dyne Therapeutics, Inc.（纳斯达克代码：DYN - 获取免费报告）在周五交易前股价跳空下跌，此前 Oppenheimer 将该股票评级从 “跑赢大盘” 下调至 “市场表现”。该股票此前收于 14.68 美元，但开盘价为 14.13 美元。Dyne Therapeutics 的股票最后交易价格为 14.13 美元，成交量为 210,969 股。</p>
<p>其他几位股票研究分析师也最近对该公司发表了看法。摩根大通将 Dyne Therapeutics 的目标价从 10.00 美元下调至 9.00 美元，并在 7 月 15 日的研究报告中给予该公司 “中性” 评级。Jones Trading 在 6 月 26 日的研究报告中开始覆盖 Dyne Therapeutics，给予 “买入” 评级和 30.00 美元的目标价。Sanford C. Bernstein 在 6 月 24 日的研究报告中开始覆盖 Dyne Therapeutics，给予 “市场表现” 评级和 13.00 美元的目标价。Chardan Capital 在 7 月 29 日的研究报告中将 Dyne Therapeutics 的目标价从 50.00 美元下调至 38.00 美元，并给予该股票 “买入” 评级。最后，Guggenheim 在 6 月 18 日的研究报告中重申了 “买入” 评级，并设定了 50.00 美元的目标价。三位研究分析师给予该股票 “强烈买入” 评级，十位给予 “买入” 评级，三位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，平均目标价为 34.07 美元。</p>
<p>获取 <strong>Dyne Therapeutics</strong> 警报：</p>
<p><strong>获取我们最新的 DYN 股票报告</strong></p>
<h2>内部活动</h2>
<p>在相关消息中，首席执行官 John Cox 在 7 月 14 日的交易中购买了 100,000 股公司的股票。每股平均价格为 9.11 美元，总价值为 911,000.00 美元。收购完成后，首席执行官持有 242,179 股公司股票，价值约为 2,206,250.69 美元。此交易代表其持股比例增加了 70.33%。该交易已在向证券交易委员会的备案中披露，相关信息可通过此超链接访问。内部人士持有公司 14.14% 的股票。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者最近调整了对该股票的持有。GAMMA Investing LLC 在第一季度将其在 Dyne Therapeutics 的持股增加了 837.5%。GAMMA Investing LLC 现在拥有 2,625 股公司股票，价值 251,000 美元，此前在该期间购买了 2,345 股。CWM LLC 在第二季度将其在 Dyne Therapeutics 的持股增加了 168.1%。CWM LLC 现在拥有 3,030 股公司股票，价值 29,000 美元，此前在上一季度购买了 1,900 股。Caitong International Asset Management Co. Ltd 在第一季度将其在 Dyne Therapeutics 的持股增加了 378.6%。Caitong International Asset Management Co. Ltd 现在拥有 3,092 股公司股票，价值 32,000 美元，此前在上一季度购买了 2,446 股。Quarry LP 在第一季度购买了 Dyne Therapeutics 的新股份，价值约为 47,000 美元。最后，Ameritas Investment Partners Inc.在第二季度将其在 Dyne Therapeutics 的持股增加了 11.1%。Ameritas Investment Partners Inc.现在拥有 9,582 股公司股票，价值 91,000 美元，此前在上一季度购买了 955 股。机构投资者和对冲基金持有公司 96.68% 的股票。</p>
<h2>Dyne Therapeutics 股票表现</h2>
<p>该公司的债务与股本比率为 0.17，流动比率为 16.83，速动比率为 16.83。该股票的市值为 20 亿美元，市盈率为-3.66，贝塔值为 1.09。该股票的 50 日移动平均线为 12.76 美元，200 日移动平均线为 11.25 美元。</p>
<p>Dyne Therapeutics（纳斯达克代码：DYN - 获取免费报告）最近在 7 月 28 日发布了季度财报。该公司报告每股收益为（0.97 美元），超过分析师一致预期的（0.99 美元）0.02 美元。研究分析师预计 Dyne Therapeutics, Inc.在当前财政年度将发布-3.44 的每股收益。</p>
<h2>关于 Dyne Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Dyne Therapeutics, Inc.是一家临床阶段的肌肉疾病公司，作为一家生物技术公司，专注于推进针对美国遗传性肌肉疾病的治疗。它正在开发一系列肌肉疾病治疗方案，包括肌强直性营养不良症 1 型、杜氏肌营养不良症和面肩肱肌营养不良症，以及使用其 FORCE 平台针对罕见骨骼肌、心脏和代谢肌肉疾病的疾病修饰治疗。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票超过 Dyne Therapeutics</li>
<li>房地产投资信托是否值得在您的投资组合中占有一席之地？</li>
<li>游戏玩家如何推动微软下一波增长</li>
<li>资产配置：成功投资组合的关键。您是否关注自己的投资组合？</li>
<li>大幅上涨警报：这三只科技股本月正在飙升</li>
<li>高飞者：2022 年 3 月的三只天然气股票</li>
<li>可口可乐股票下跌——CELH 是您投资组合所需的增长吗？</li>
</ul>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 Dyne Therapeutics 吗？</h2>
<p>在您考虑 Dyne Therapeutics 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Dyne Therapeutics 并不在名单上。</p>
<p>虽然 Dyne Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Dyne Therapeutics（纳斯达克代码：DYN）股价在 Oppenheimer 将其评级从 “跑赢大盘” 下调至 “市场表现” 后出现跳空下跌，开盘价为 14.13 美元，前一交易日收盘价为 14.68 美元。分析师的评级意见不一，目标价范围从 9.00 美元到 50.00 美元不等。首席执行官 John Cox 以每股 9.11 美元购买了 100,000 股，显著增加了他的持股比例。机构投资者持有该股票的 96.68%。公司报告的季度每股收益为（-0.97 美元），略微超过预期，专注于肌肉疾病的治疗药物</p>

<p>Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) shares gapped down prior to trading on Friday after Oppenheimer downgraded the stock from an outperform rating to a market perform rating. The stock had previously closed at $14.68, but opened at $14.13. Dyne Therapeutics shares last traded at $14.13, with a volume of 210,969 shares changing hands.</p>
<div class="lb-trans"><p>Dyne Therapeutics, Inc.（纳斯达克代码：DYN - 获取免费报告）在周五交易前股价跳空下跌，此前 Oppenheimer 将该股票评级从 “跑赢大盘” 下调至 “市场表现”。该股票此前收于 14.68 美元，但开盘价为 14.13 美元。Dyne Therapeutics 的股票最后交易价格为 14.13 美元，成交量为 210,969 股。</p>
</div><p>Several other equities research analysts have also recently weighed in on the company. JPMorgan Chase &amp; Co. decreased their target price on Dyne Therapeutics from $10.00 to $9.00 and set a &#34;neutral&#34; rating for the company in a research note on Tuesday, July 15th. Jones Trading started coverage on Dyne Therapeutics in a research note on Thursday, June 26th. They set a &#34;buy&#34; rating and a $30.00 target price for the company. Sanford C. Bernstein started coverage on Dyne Therapeutics in a research note on Tuesday, June 24th. They set a &#34;market perform&#34; rating and a $13.00 target price for the company. Chardan Capital cut their price target on Dyne Therapeutics from $50.00 to $38.00 and set a &#34;buy&#34; rating on the stock in a research report on Tuesday, July 29th. Finally, Guggenheim reaffirmed a &#34;buy&#34; rating and set a $50.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, June 18th. Three research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of &#34;Moderate Buy&#34; and an average target price of $34.07.</p>
<div class="lb-trans"><p>其他几位股票研究分析师也最近对该公司发表了看法。摩根大通将 Dyne Therapeutics 的目标价从 10.00 美元下调至 9.00 美元，并在 7 月 15 日的研究报告中给予该公司 “中性” 评级。Jones Trading 在 6 月 26 日的研究报告中开始覆盖 Dyne Therapeutics，给予 “买入” 评级和 30.00 美元的目标价。Sanford C. Bernstein 在 6 月 24 日的研究报告中开始覆盖 Dyne Therapeutics，给予 “市场表现” 评级和 13.00 美元的目标价。Chardan Capital 在 7 月 29 日的研究报告中将 Dyne Therapeutics 的目标价从 50.00 美元下调至 38.00 美元，并给予该股票 “买入” 评级。最后，Guggenheim 在 6 月 18 日的研究报告中重申了 “买入” 评级，并设定了 50.00 美元的目标价。三位研究分析师给予该股票 “强烈买入” 评级，十位给予 “买入” 评级，三位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，平均目标价为 34.07 美元。</p>
</div><p>Get <strong>Dyne Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Dyne Therapeutics</strong> 警报：</p>
</div><p><strong>Get Our Latest Stock Report on DYN</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 DYN 股票报告</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In related news, CEO John Cox bought 100,000 shares of the company's stock in a transaction dated Monday, July 14th. The shares were acquired at an average price of $9.11 per share, with a total value of $911,000.00. Following the completion of the acquisition, the chief executive officer owned 242,179 shares in the company, valued at approximately $2,206,250.69. This trade represents a 70.33% increase in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Insiders own 14.14% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席执行官 John Cox 在 7 月 14 日的交易中购买了 100,000 股公司的股票。每股平均价格为 9.11 美元，总价值为 911,000.00 美元。收购完成后，首席执行官持有 242,179 股公司股票，价值约为 2,206,250.69 美元。此交易代表其持股比例增加了 70.33%。该交易已在向证券交易委员会的备案中披露，相关信息可通过此超链接访问。内部人士持有公司 14.14% 的股票。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC increased its holdings in shares of Dyne Therapeutics by 837.5% in the first quarter. GAMMA Investing LLC now owns 2,625 shares of the company's stock valued at $251,000 after purchasing an additional 2,345 shares during the period. CWM LLC boosted its stake in shares of Dyne Therapeutics by 168.1% in the second quarter. CWM LLC now owns 3,030 shares of the company's stock valued at $29,000 after buying an additional 1,900 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in shares of Dyne Therapeutics by 378.6% in the first quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company's stock valued at $32,000 after buying an additional 2,446 shares in the last quarter. Quarry LP purchased a new stake in shares of Dyne Therapeutics in the first quarter valued at approximately $47,000. Finally, Ameritas Investment Partners Inc. boosted its stake in shares of Dyne Therapeutics by 11.1% in the second quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company's stock valued at $91,000 after buying an additional 955 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近调整了对该股票的持有。GAMMA Investing LLC 在第一季度将其在 Dyne Therapeutics 的持股增加了 837.5%。GAMMA Investing LLC 现在拥有 2,625 股公司股票，价值 251,000 美元，此前在该期间购买了 2,345 股。CWM LLC 在第二季度将其在 Dyne Therapeutics 的持股增加了 168.1%。CWM LLC 现在拥有 3,030 股公司股票，价值 29,000 美元，此前在上一季度购买了 1,900 股。Caitong International Asset Management Co. Ltd 在第一季度将其在 Dyne Therapeutics 的持股增加了 378.6%。Caitong International Asset Management Co. Ltd 现在拥有 3,092 股公司股票，价值 32,000 美元，此前在上一季度购买了 2,446 股。Quarry LP 在第一季度购买了 Dyne Therapeutics 的新股份，价值约为 47,000 美元。最后，Ameritas Investment Partners Inc.在第二季度将其在 Dyne Therapeutics 的持股增加了 11.1%。Ameritas Investment Partners Inc.现在拥有 9,582 股公司股票，价值 91,000 美元，此前在上一季度购买了 955 股。机构投资者和对冲基金持有公司 96.68% 的股票。</p>
</div><h2>Dyne Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Dyne Therapeutics 股票表现</h2>
</div><p>The company has a debt-to-equity ratio of 0.17, a current ratio of 16.83 and a quick ratio of 16.83. The stock has a market capitalization of $2.00 billion, a PE ratio of -3.66 and a beta of 1.09. The stock has a 50 day moving average of $12.76 and a two-hundred day moving average of $11.25.</p>
<div class="lb-trans"><p>该公司的债务与股本比率为 0.17，流动比率为 16.83，速动比率为 16.83。该股票的市值为 20 亿美元，市盈率为-3.66，贝塔值为 1.09。该股票的 50 日移动平均线为 12.76 美元，200 日移动平均线为 11.25 美元。</p>
</div><p>Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings results on Monday, July 28th. The company reported ($0.97) earnings per share for the quarter, beating analysts' consensus estimates of ($0.99) by $0.02. Research analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Dyne Therapeutics（纳斯达克代码：DYN - 获取免费报告）最近在 7 月 28 日发布了季度财报。该公司报告每股收益为（0.97 美元），超过分析师一致预期的（0.99 美元）0.02 美元。研究分析师预计 Dyne Therapeutics, Inc.在当前财政年度将发布-3.44 的每股收益。</p>
</div><h2>About Dyne Therapeutics</h2>
<div class="lb-trans"><h2>关于 Dyne Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.</p>
<div class="lb-trans"><p>Dyne Therapeutics, Inc.是一家临床阶段的肌肉疾病公司，作为一家生物技术公司，专注于推进针对美国遗传性肌肉疾病的治疗。它正在开发一系列肌肉疾病治疗方案，包括肌强直性营养不良症 1 型、杜氏肌营养不良症和面肩肱肌营养不良症，以及使用其 FORCE 平台针对罕见骨骼肌、心脏和代谢肌肉疾病的疾病修饰治疗。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Dyne Therapeutics</li>
<li>Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?</li>
<li>How Gamers Are Powering Microsoft’s Next Wave of Growth</li>
<li>Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?</li>
<li>Big Gains Alert: These 3 Tech Stocks Are Surging This Month</li>
<li>High Flyers: 3 Natural Gas Stocks for March 2022</li>
<li>Coca-Cola Stock Dips—Is CELH the Growth Your Portfolio Needs?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Dyne Therapeutics</li>
<li>房地产投资信托是否值得在您的投资组合中占有一席之地？</li>
<li>游戏玩家如何推动微软下一波增长</li>
<li>资产配置：成功投资组合的关键。您是否关注自己的投资组合？</li>
<li>大幅上涨警报：这三只科技股本月正在飙升</li>
<li>高飞者：2022 年 3 月的三只天然气股票</li>
<li>可口可乐股票下跌——CELH 是您投资组合所需的增长吗？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Dyne Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Dyne Therapeutics 吗？</h2>
</div><p>Before you consider Dyne Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Dyne Therapeutics 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Dyne Therapeutics 并不在名单上。</p>
</div><p>While Dyne Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Dyne Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Dyne Therapeutics (NASDAQ:DYN) 的股价在分析师下调评级后出现跳空低开